Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Biocon Limited, commonly referred to as Biocon, is a leading Indian pharmaceutical preparation manufacturer headquartered in Bangalore, India. Established in 1978, the company has grown to become a prominent player in the global biopharmaceutical industry, with a strong presence across Asia, North America, and Europe.
Specialising in the development and manufacturing of biosimilars, generic pharmaceuticals, and novel biologics, Biocon is recognised for its innovative approach to healthcare solutions. Its core products include insulin, monoclonal antibodies, and other biopharmaceuticals that address a range of therapeutic areas such as diabetes, oncology, and autoimmune diseases.
Biocon’s commitment to quality and affordability has earned it a notable market position, making it one of India’s most respected biopharmaceutical companies. Its focus on research and development continues to drive its reputation as a pioneer in the pharmaceutical preparation manufacturing industry.
+16 vs industry average
Biocon’s score of 58 is higher than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Scope 3 accounts for ••• of total emissions.
Biocon Limited, a Pharmaceutical Preparation Manufacturing company headquartered in India, reported its latest emissions data for 2025, with Scope 1 emissions at 34,588,000 kg CO2e, Scope 2 at 121,050,000 kg CO2e, and Scope 3 at 341,324,000 kg CO2e. In 2024, the company's Scope 1 emissions were 38,428,000 kg CO2e, Scope 2 were 116,989,000 kg CO2e, and Scope 3 were 126,110,000 kg CO2e. For 2023, Biocon reported Scope 1 emissions of 45,715,000 kg CO2e and Scope 2 emissions of 138,510,000 kg CO2e.
Biocon has set a near-term absolute target to decrease its Scope 1 and Scope 2 emissions by 25% by the end of FY29, using FY20 data as the baseline. This commitment is documented in their 2024 Integrated Annual Report and the 2024 BRSR GRI ESG Databook. Additionally, Biocon has an internal long-term absolute target of a 20% reduction in Scope 1 and Scope 2 emissions by 2032, from a FY22 baseline.
2025
Near-zero scope 1 & 2
Target to achieve near-zero emissions for direct operations and purchased energy
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
No scope 3 category breakdown has been disclosed yet.


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more